https://www.selleckchem.com/pr....oducts/wortmannin.ht
Aim Poly(ADP-ribose) polymerase inhibitors (PARPIs) improved progression-free survival among patients with recurrent ovarian cancer. This meta-analysis examined the effectiveness of PARPIs as maintenance strategy for newly diagnosed patients with advanced high-grade ovarian cancer with or without mutations. Materials methods Using defined selection criteria, a literature search identified four eligible randomized clinical trials involving 2386 patients. Results Compared with placebo maintenance, PARPIs achieved a 46% reduction
Like
Comment
Share
